Disruptive research to improve brain
tumour outcomes
tumour outcomes
Slide 1
Slide 2
Risk free solutions for all brain
tumour patients
tumour patients
Slide 3
Blockchain technology for clinical information management
What we do
Revolutionizing Brain Cancer Diagnosis and Treatment
Focus
Disruptive research in minimally invasive brain cancer diagnostics and therapeutics
Science
Single Cell multinomic approaches to answer the most demanding questions in neuro-oncology research
Technology
Blockchain based auditable distributed ledgers to collect and manage all clinical information
Products
Clinician lead products to address specific needs in current care pathway
Artificial Intelligence
Proprietary AI/ML algorithms trained on large databases for near perfect precision
Alliances
Geographically agnostic cloud based models allowing worldwide access and infinite scalability
Our Science
Introducing Liquid Biopsy, a minimally invasive diagnostic tool for brain tumours using a few drops of blood
Changing Paradigm In Brain Tumour Diagnostics
Partners
Partnerships
In adddition to our assosiation with the largest hospital chains in India, Exsegen is also a member of the Global Brain Liquid Biposy Consortium which is at the forefront of the global effort in standardizing the use of liquid biopsy in brain tumours.
Ongoing Clinical Trials
Exsegen’s ongoing CTRI-approved clinical trial is to diagnose brain lesions with a specificity and sensitivity approaching a traditional biopsy in any patient having a radiological lesion that may represent a brain tumour. Further details on the clinical trial can be accessed using the link below
Our Products
Exsegen’s product pipeline embraces the transformational advantages of Liquid Biopsy and deep tech platforms. We are in the process of developing and bringing new products to the market to improve Brain Cancer patient outcomes.
Elsy, Our Clinial Management Solution
ELSY represents a technology solution that has the potential to revolutionize the way clinical trials are conducted for Liquid Biopsy. ELSY is designed to increase transparency and accountability in the trial process, from study design and protocol development to data collection and analysis. ELSY can potentially reduce study costs by eliminating manual processes, reducing errors and delays, and improving overall efficiency.
Meet the team
Dr. Amitava Ray
Founder & CEO
Surya Madiraju
Co-Founder
Kiran Prathapa
CTO
Vikas Pawar
COO
Goutam Bhattacharyya, PhD
Director & General Counsel
Pallavi Goel
Bio-Tech Specialist
Vijay Sreegiriraju
VP, Technology
Moona Chauhan
VP, Sales & Marketing
KVRN Kiran Kumar
Designation
Pankaj Mishra
Designation
Advisors
Jyothi Sagar
Partha Mazumdar
Indrajeet Kaur
Venu Polineni
Publications & Posters
Our technical publications are a critical component of our strategy for staying at the forefront of thought leadership in the Brain cancer research. By sharing our research findings and technical expertise with the broader scientific community, we want to continue to innovate and grow knowledge in the years to come.
Careers
We appreciate your interest in joining our growing team. This section provides the resource for who are interested in learning more about Exsegen's culture, values, and available job opportunities.